The use of copper-lowering therapy with tetrathiomolybdate in medicine

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.18, Iss.1, 2009-01, pp. : 89-97

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Copper Lowering Therapy With Tetrathiomolybdate as an Antiangiogenic Strategy in Cancer

Current Cancer Drug Targets, Vol. 5, Iss. 3, 2005-05 ,pp. : 195-202

Bentham Science Publishers

Access to resources Recommend Favorite

Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm

By Khan Gazala Merajver Sofia

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 4, 2009-04 ,pp. : 541-548

Informa Healthcare

Access to resources Recommend Favorite

A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer

By Gartner Elaina Griffith Kent Pan Quintin Brewer George Henja Gwen Merajver Sofia Zalupski Mark

Investigational New Drugs, Vol. 27, Iss. 2, 2009-04 ,pp. : 159-165

Springer Publishing Company

Access to resources Recommend Favorite

Early initiation of lipid-lowering therapy improves use in ACS

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 476, 2005-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Lipid-lowering therapy use below par among Danish IHD patients

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 452, 2004-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite